Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Mammary Gland Biology and Neoplasia
Published in: Journal of Mammary Gland Biology and Neoplasia 1/2007

01-03-2007

The Beginning of the End: Death Signaling in Early Involution

Authors: Fiona O. Baxter, Kevin Neoh, Maxine C. Tevendale

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 1/2007

Login to get access

Abstract

Mammary gland involution occurs in two distinct phases: an early, reversible phase, involving extensive apoptosis of the secretory alveolar epithelium without major changes in gland architecture, and a later, irreversible phase, involving remodelling of the gland to its pre-pregnancy state. Multiple signalling pathways are known to be important during early involution, however the precise triggers remain elusive. This review summarizes the roles of a number of key pathways (NF-κB, PI(3)K, Stat3, and TGFβ) in the first phase of involution.
Literature
1.
Marti A, Jehn B, Costello E, Keon N, Ke G, Martin F, Jaggi R. Protein kinase A and AP-1 (c-Fos/JunD) are induced during apoptosis of mouse mammary epithelial cells. Oncogene 1994;9(4):1213–23.PubMed
2.
Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, et al. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 1996;122:181–93.PubMed
3.
Furth PA, Bar-Peled U, Li M. Apoptosis and mammary gland involution: reviewing the process. Apoptosis 1997;2(1):19–24.PubMed
4.
Melino G, Knight RA, Nicotera P. How many ways to die? How many different models of cell death? Cell Death Differ 2005;12(2):1457–62.PubMed
5.
Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770–6.PubMed
6.
Clarkson RW, Wayland MT, Lee J, Freeman T, Watson CJ. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res 2004;6(2):92–109.
7.
Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, et al. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res 2004;6:R75–91.PubMed
8.
Baxter FO, Came PJ, Abell K, Kedjouar B, Huth M, Rajewsky K, et al. IKKb/2 induces TWEAK and apoptosis in mammary epithelial cells. Development 2006;133(17):3485–94.PubMed
9.
Rosenblatt J, Raff MC, Cramer LP. An epithelial cell destined for apoptosis signals its neighbors to extrude it by and actin- and myosin-dependent mechanism. Curr Biol. 2001;11(23):1847–57.PubMed
10.
Feng ZW, Marti A, Jehn B, Altermatt HJ, Chicaiza G, Jaggi R. Glucocorticoid and progesterone inhibit involution and programmed cell-death in the mouse mammary-gland. J Cell Biol. 1995;131:1095–103.PubMed
11.
Li M, Liu X, Robinson G, Bar-Peled U, Wagner KU, Young WS, Hennighausen L, et al. Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc Natl Acad Sci USA. 1997;94(7):3425–30 (Apr 1).PubMed
12.
Nguyen AV, Pollard JW. Transforming growth factor beta 3 induces cell death during the first stage of mammary gland involution. Development 2000;127:3107–18.PubMed
13.
Kritikou EA, Sharkey A, Abell K, Came PJ, Anderson E, Clarkson RWE, et al. A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development 2003;130(15):3459–68.PubMed
14.
Schere-Levy C, Buggiano V, Quaglino A, Gattelli A, Cirio MC, Piazzon I, et al. Leukemia inhibitory factor induces apoptosis of the mammary epithelial cells and participates in mouse mammary gland involution. Exp Cell Res 2003;282(1):35–47 (Jan 1).PubMed
15.
Clarkson RW, Heeley JL, Chapman R, Aillet F, Hay RT, Wyllie AH, et al. NF-κB inhibits apoptosis in murine mammary epithelia. J Biol Chem 2000;275(17):12737–42.PubMed
16.
Schmitt-Ney M, Happ B, Hofer P, Hynes NE, Groner B. Mammary gland-specific nuclear factor activity is positively regulated by lactogenic hormones and negatively by milk stasis. Mol Endocrinol 1992;6(12):1988–97.PubMed
17.
Liu X, Robinson GW, Hennighausen L. Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol 1996;10(12):1496–506.PubMed
18.
Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, et al. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res 2004;6:R75–91.PubMed
19.
Monks J, Rosner D, Geske FJ, Lehman L, Neville MC, Fadok VA. Epithelial cells as phagocytes: apoptotic epithelial cells are engulfed by mammary alveolar epithelial cells and repress inflammatory mediator release. Cell Death Differ 2005;12:107–14.PubMed
20.
Hanayama R, Nagata S. Impaired involution of mammary glands in the absence of milk fat globule EGF factor 8. Proc Natl Acad Sci USA 2005;102(46):16886–91.PubMed
21.
Atabai K, Fernandez, R, Huang, X, Ueki, I, Kline, A, Li, Y, et al. Mfge8 is critical for mammary gland remodeling during involution. Mol Biol Cell 2005;16(12):5528–37.PubMed
22.
23.
Schwertfeger KL, Richert, MM, Anderson, SM. Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol 2001;15(6):867–81.PubMed
24.
Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 1999;13:2604–16.PubMed
25.
26.
Clarkson RW, Boland MP, Kritikou EA, Lee JM, Freeman TC, Tiffen PG, et al. The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development. Mol Endocrinol 2006;20(3):675–85.PubMed
27.
Kritikou EA, Sharkey A,. Abell K, Came PJ, Anderson E, Clarkson RWE, et al. A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development 2003;130(15):3459–68.PubMed
28.
Thangaraju M, Rudelius M, Bierie B, Raffeld M, Sharan S, Hennighausen L, et al. C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution. Development 2005;132:4675–85.PubMed
29.
Tiffen P. PhD Thesis, University of Cambridge; 2006.
30.
Heinrich PC, Behrmann I, Muller-Newen G, Shaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334(2):297–314PubMed
31.
Kritikou EA, Sharkey A, Abell K, Came PJ, Anderson E, Clarkson RWE, et al. A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development 2003;130(15):3459–68.PubMed
32.
Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, et al. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells 2005;10:1051–63.PubMed
33.
Wymann MP, Zvelebil M, Laffargue M. Phosphoinositide 3-kinase signalling—which way to target? TIPS 2003;24(7):366–76.PubMed
34.
Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001;70:535–602.PubMed
35.
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95(1):29–39.PubMed
36.
Hunter S, Koch BL, Anderson SM. Phosphorylation of cbl after stimulation of Nb2 cells with prolactin and its association with phosphatidylinositol 3-kinase. Mol Endocrinol 1997;11(9):1213–22.PubMed
37.
Hunter S, Burton EA, Wu SC, Anderson SM. Fyn associates with Cbl and phosphorylates tyrosine 731 in Cbl, a binding site for phosphatidylinositol 3-kinase. J Biol Chem 1999;274(4):2097–106.PubMed
38.
Strange R, Metcalfe T, Thackray L, Dang M. Apoptosis in normal and neoplastic mammary gland development. Microsc Res Tech 2001;52(2):171–81.PubMed
39.
Widmann C, Gibson S, Johnson GL. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J Biol Chem 1998;273(12):7141–7.PubMed
40.
Gilmore AP, Metcalfe AD, Romer LH, Streuli CH. Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. J Cell Biol 2000;149(2):431–46.PubMed
41.
Strange R, Metcalfe T, Thackray L, Dang M. Apoptosis in normal and neoplastic mammary gland development. Microsc Res Tech 2001;52(2):171–81.PubMed
42.
Farrelly N, Lee YJ, Oliver J, Dive C, Streuli CH. Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J Cell Biol 1999;144:1337–47.PubMed
43.
Neuenschwander S, Schwartz A, Wood TL, Roberts CT, Henninghausen L, Leroith D. Involution of the lactating mammary-gland is inhibited by the Igf system in a transgenic mouse model. J Clin Invest 1996;97:2225–32.PubMed
44.
Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM. Targeted expression of des(1–3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 1996;137:321–30.PubMed
45.
Moorehead RA, Fata JE, Johnson MB, Khokha R. Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice. Cell Death Differ 2001;8:16–29.PubMed
46.
Tonner E, Barber MC, Travers MT, Logan A, Flint DJ. Hormonal control of insulin-like growth factor-binding protein-5 production in the involuting mammary gland of the rat. Endocrinology 1997;138:5101–7.PubMed
47.
Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 1999;13:2604–16.PubMed
48.
Schwertfeger KL, McManaman JL, Palmer CA, Neville MC, Anderson SM. Expression of constitutively activated Akt in the mammary gland leads to excess lipid synthesis during pregnancy and lactation. J Lipid Res 2003;44(6):1100–12.PubMed
49.
Schwertfeger KL, Richert MM, Anderson SM. Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol 2001;15(6):867–81.PubMed
50.
Abell K, Bilancio A, Clarkson RW, Tiffen PG, Altaparmakov AI, Burdon TG, et al. Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat Cell Biol 2005;7(4):392–8.PubMed
51.
Strange R, Metcalfe T, Thackray L, Dang M. Apoptosis in normal and neoplastic mammary gland development. Microsc Res Tech 2001;52(2):171–81.PubMed
52.
Schwertfeger KL, Richert MM, Anderson SM. Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol 2001;15(6):867–81.PubMed
53.
Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 2001;21(6):2203–12.PubMed
54.
Ackler S, Ahmad S, Tobias C, Johnson MD, Glazer RI. Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene 2002;21(2):198–206.PubMed
55.
Abell K, Bilancio A, Clarkson RW, Tiffen PG, Altaparmakov AI, Burdon TG, et al. Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat Cell Biol 2005;7(4):392–8.PubMed
56.
Lacher MD, Siegenthaler A, Jager R, Yan X, Hett S, Xuan L, et al. Role of DDC-4/sFRP-4, a secreted frizzled-related protein, at the onset of apoptosis in mammary involution. Cell Death Differ 2003;10(5):528–38.PubMed
57.
Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282(5392):1318–21.PubMed
58.
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96(6):857–68.PubMed
59.
Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000;10(19):1201–4.PubMed
60.
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509–12.PubMed
61.
Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422–6.PubMed
62.
Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, et al. Target genes of beta-catenin-T cell-factor lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999;96:1603–1608.PubMed
63.
Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999;9(11):601–4.PubMed
64.
Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001;15:2203–8.PubMed
65.
Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001a;276(42):38349–52.PubMed
66.
Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB 3rd, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001b;292(5522):1728–31.PubMed
67.
Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 2003 Jul;112(2):197–208. Epub 2003 Jul 3.PubMed
68.
Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 2005;25(5):1869–78 (Mar).PubMed
69.
Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, Watanabe T, et al. Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development 2005;132(13):2943–54 (Jul).PubMed
70.
Boxer RB, Stairs DB, Dugan KD, Notarfrancesco KL, Portocarrero CP, Keister BA, et al. Isoform-specific requirement for Akt1 in the developmental regulation of cellular metabolism during lactation. Cell Metab. 2006;4(6):475–90.PubMed
71.
Roberts AB, Sporn MB. The transforming growth factor-betas. In: Roberts AB, editor. Peptide Growth Factors and Their Receptors. Berlin Heidelberg New York: Springer; 1990. p. 419–72.
72.
Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett 2006;580(12):2811–20.PubMed
73.
Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massague J. The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell 2001;8(3):671–82.PubMed
74.
Zhang Y, Derynck R. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol 1999;9:274–9.PubMed
75.
Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000;12:235–43.PubMed
76.
Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett. 2006;580(12):2811–20.PubMed
77.
Roberts AB, Sporn MB. Differential expression of the TGF-beta isoforms in embryogenesis suggests specific roles in developing and adult tissues. Mol Reprod Dev 1992;32(2):91–8 (June).PubMed
78.
Daniel CW, Robinson S, Silberstein GB. The transforming growth factors beta in development and functional differentiation of the mouse mammary gland. Adv Exp Med Biol 2001;501:61–70.PubMed
79.
Serra R, Crowley MR. TGF-beta in mammary gland development and breast cancer. Breast Dis 2003;18:61–73.PubMed
80.
Nguyen AV, Pollard JW. Transforming growth factor beta 3 induces cell death during the first stage of mammary gland involution. Development 2000;127:3107–18.PubMed
81.
Prince JM, Klinowska TC, Marshman E, Lowe ET, Mayer U, Miner J, et al. Cell-matrix interactions during development and apoptosis of the mouse mammary gland in vivo. Dev Dyn 2002;223(4):497–516.PubMed
82.
Streuli CH, Schmidhauser C, Kobrin M, Bissell MJ, Derynck R. Extracellular-matrix regulates expression of the TGF-beta-1 gene. J Cell Biol 1993;120:253–60.PubMed
83.
Siegel PM, Massagué, J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003;3:807–20.PubMed
84.
Yang YA, Tang B, Robinson G, Hennighausen L, Brodie SG, Deng CX, et al. Smad3 in the mammary epithelium has a nonredundant role in the induction of apoptosis, but not in the regulation of proliferation or differentiation by transforming growth factor-beta. Cell Growth Differ 2002;13(3):123–30.PubMed
85.
Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA. TGF-β-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat. Cell Biol 2001;3:708–14.PubMed
86.
Yu L, Hebert MC, Zhang YE. TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J 2002;21:3749–59.PubMed
87.
Gottfried Y, Rotem A, Lotan R, Steller H, Larisch S. The mitochondrial ARTS protein promotes apoptosis through targeting XIAP. EMBO J 2004;23:1627–35.PubMed
88.
Schuster N, Krieglstein K. Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res 2002;307(1):1–14.PubMed
89.
Remy I, Montmarquette A, Michnick SW. PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3. Nat Cell Biol 2004;6:358–65.PubMed
90.
Conery AR, Cao Y, Thompson EA, Townsen CM, Ko TC Jr, Luo K. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β induced apoptosis. Nat Cell Biol 2004;6:366–72.PubMed
91.
Nguyen AV, Pollard JW. Transforming growth factor beta 3 induces cell death during the first stage of mammary gland involution. Development 2000;127:3107–18.PubMed
92.
Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000;18:621–63.PubMed
93.
Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappaB signaling pathway. Science 2001;293(5534):1495–9.PubMed
94.
Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, et al. IKKα provides an essential link between RANK signalling and cyclin D1 expression during mammary gland development. Cell 2001;107:763–75.PubMed
95.
Brantley DM, Yull FE, Muraoka RS, Hicks DJ, Cook CM, Kerr LD. Dynamic expression and activity of NF-κB during post-natal mammary gland morphogenesis. Mech Dev 2000;97(1–2):149–55.PubMed
96.
Geymayer S, Doppler W. Activation of the NF-κB p50/p65 is regulated in the developing mammary gland and inhibits STAT5-mediated beta-casein gene expression. FASEB J 2000;14:1159–70.PubMed
97.
Henninghausen L, Robinson GW. Signaling pathways in mammary gland development. Dev Cell 2001;1:467–75.
98.
Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000;18:621–63.PubMed
99.
Baetu TM, Kwon H, Sharma S, Grandvaux N, Hiscott J. Disruption of NF-kappaB signalling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 2001;167(6):3164–73.PubMed
100.
Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappaB and AP-1. Mol Cell 1998;1(4):543–51.PubMed
101.
Trede NS, Tsytsykova AV, Chatila T, Goldfeld AE, Geha RS. Transcriptional activation of the human TNF-alpha promoter by superantigen in human monocytic cells: role of NF-kappaB. J Immunol 1995;155:902–8.PubMed
102.
Song J, Sapi E, Brown W, Nilsen J, Tartaro K, Kacinski BM, et al. Roles of Fas and Fas ligand during mammary gland remodelling. J Clin Invest 2000;106(10):1209–20.PubMedCrossRef
103.
Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signalling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003;14:337–48.PubMed
104.
Green KA, Streuli CH. Apoptosis regulation in the mammary gland. Cell Mol Life Sci ;2004;61(15):1867–83 (Aug).PubMed
105.
Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000;18:621–63.PubMed
106.
Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, et al. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res 2004;6:R75–91.PubMed
Metadata
Title
The Beginning of the End: Death Signaling in Early Involution
Authors
Fiona O. Baxter
Kevin Neoh
Maxine C. Tevendale
Publication date
01-03-2007
Published in
Journal of Mammary Gland Biology and Neoplasia / Issue 1/2007
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI
https://doi.org/10.1007/s10911-007-9033-9

Other articles of this Issue 1/2007

Journal of Mammary Gland Biology and Neoplasia 1/2007 Go to the issue

OriginalPaper

Mammary Gland Involution as a Multi-step Process

OriginalPaper

Roles of the Innate Immune System in Mammary Gland Remodeling During Involution

OriginalPaper

The Molecular Culprits Underlying Precocious Mammary Gland Involution

OriginalPaper

The Declining Phase of Lactation: Peripheral or Central, Programmed or Pathological?

OriginalPaper

Extracellular Proteolysis in Transgenic Mouse Models of Breast Cancer

Preface

Involution: Completing the Cycle
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits